2019 cohort | 2020 cohort | |
---|---|---|
Patients | 42 | 62 |
Observation time, person-days | 1130 | 1000 |
Gender (male) | 24 (57.1) | 41 (66.1) |
Age, years | 64.5 (52–76) | 70 (61–79) |
Admission to the ICU | ||
Other ward | 11 (26.2) | 31 (50.0) |
Other hospital | 2 (4.8) | 5 (8.1) |
Emergency Department | 29 (69.0) | 26 (41.9) |
Coexisting conditions | ||
Hypertension | 22 (52.4) | 27 (43.6) |
Diabetes mellitus | 10 (23.8) | 10 (16.1) |
Asthma | 1 (2.4) | 4 (6.5) |
Coronary heart disease | 2 (4.8) | 11 (17.7) |
Chronic kidney disease | 3 (7.1) | 5 (8.1) |
Chronic liver disease | 2 (4.6) | 0 (0.0) |
Active cancer | 4 (9.5) | 7 (11.3) |
Immunodeficiency | 5 (11.9) | 1 (1.6) |
ICU deaths | 10 (23.8) | 35 (56.5) |
Mortality rate (95% CI) per 1000 patient-days | 8.8 (4.8–15.0) | 35.0 (25.8–46.4) |
Length of ICU stay, days | 14.5 (7–36) | 13 (6–21) |
Central venous catheter, days | 15.5 (7–33.5) | 14 (6–23) |
Urinary catheter, days | 14.5 (7–35) | 13 (6.5–22) |
Invasive ventilation, days | 13 (4–35) | 8 (5–19) |
Patients with invasive ventilation | 38 (90.5) | 53 (85.5) |
Patients with at least one HAI | 11 (26.2) | 27 (43.6) |
Patients with at least one dr-HAI | 2 (4.8) | 20 (32.3) |
HAI per patient | 0.33 (0.61) | 0.73 (0.93) |
dr-HAI per patient | 0.05 (0.22) | 0.44 (0.69) |
HAI per infected patient | 1.27 (0.48) | 1.67 (0.62) |
dr-HAI per infected patient | 1.0 (0.0) | 1.35 (0.49) |
Antibiotic consumption before the first HAI | ||
Carbapenems | 40 (95.2) | 51 (82.3) |
Extended spectrum cephalosporins | 15 (35.7) | 6 (9.7) |
Glycopeptides | 14 (33.3) | 29 (46.8) |
Macrolides | 3 (7.1) | 15 (24.2) |
Penicillins + beta lactamase inhibitors | 21 (50.0) | 31 (50.0) |